Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904335 | 0.89 | SCN9A (0.48) | HTR2ACYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL903153 | 0.89 | SCN9A (0.48) | HTR2ACYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL12051151 | 0.89 | HTR2A (0.52) | HTR2ACYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL13006934 | 0.81 | SCN9A (0.49) | HTR2ACYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL4431910 | 0.81 | CYP3A4 (0.58) | HTR2ACYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL6368381 | 0.80 | SCN9A (0.48) | HTR2ACYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL4431788 | 0.80 | CYP3A4 (0.60) | HTR2ACYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL1260727 | 0.80 | CYP3A4 (0.61) | CYP2C9CYP3A4CYP2C19SCN9ACYP2D6 | |
| SCHEMBL14452260 | 0.79 | CYP3A4 (0.59) | HTR2ACYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL1261240 | 0.79 | CYP3A4 (0.62) | CYP2C9CYP3A4CYP2C19SCN9ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2530082-A1 | Process for preparing 2, 3-disubstituted indoles | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-7851625-B2 | Process for preparing 2,3-disubstituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| US-7642352-B2 | Process for preparing 2,3-disubstituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-20090264655-A1 | PROCESS FOR PREPARING 2,3-DISUBSTITUTED INDOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20070249629-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE | 2007-10-25 | — | — | US | disclosed |
| US-20070249629-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE | 2007-10-25 | — | — | US | disclosed |
| US-20070249629-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE | 2007-10-25 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| CN-1984908-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-06-20 | — | — | CN | disclosed |
| EP-1771442-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2007019674-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| US-20060052418-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| WO-2006007693-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264655-A1 | PROCESS FOR PREPARING 2,3-DISUBSTITUTED INDOLES | DCLK2, DCLK1, TTL | HTR2A 209/4885CYP2C9 1737/4885CYP3A4 1243/4885 |
| US-20070249629-A1 | Viral Polymerase Inhibitors | RPP30, POLR2A, POLR1E | HTR2A 4639/4885CYP2C9 693/4885CYP3A4 1402/4885 |
| US-20060052418-A1 | Viral polymerase inhibitors | RPP30, POLR2A, POLR1E | HTR2A 4639/4885CYP2C9 693/4885CYP3A4 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.